Renovaro (Renovaro) Net Margin %

: 0.00% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Renovaro's Net Income for the three months ended in Dec. 2023 was $-4.53 Mil. Renovaro's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Renovaro's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Renovaro's Net Margin % or its related term are showing as below:

RENB's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -163.69
* Ranked among companies with meaningful Net Margin % only.

Renovaro Net Margin % Historical Data

The historical data trend for Renovaro's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Annual Data

Trend

Mar13

Dec14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Margin %

Renovaro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, Renovaro's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovaro Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Renovaro's Net Margin % distribution charts can be found below:

* The bar in red indicates where Renovaro's Net Margin % falls into.

Renovaro Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Renovaro's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-39.684	/	0
	=	%

Renovaro's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.529	/	0
	=	%

Renovaro (NAS:RENB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Renovaro Net Margin % Related Terms

Thank you for viewing the detailed overview of Renovaro's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro (Renovaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

2Q5:Germany

Address

2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067

Website

https://www.enochianbio.com

Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.

Executives

Leni Boeren	director	2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks	director	CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard	10 percent owner	VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette	officer: Executive Vice President	2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu	10 percent owner	2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev	director, 10 percent owner	FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler	other: Former director see note below	330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol	director	606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen	director	STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche	officer: Chief Financial Officer	318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne	director	NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William	10 percent owner	8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie	director, officer: CEO; President	C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060